[
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
    "title": "Kvartalsrapport Q1 2026",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a33ca736461d70a771af7251d5d201e1f",
    "date": "2026-05-12",
    "period": "2026-q1",
    "form_type": "interim-report",
    "report_key": "2026:q1",
    "filename": "05111212.pdf",
    "text_chars": 40158,
    "sha256": "eec9efb8ab54a89d5132de2b301defe81e5efcbe56128a634b54614089bd85f6",
    "url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
    "absolute_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
    "txt_url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
        "chars": 40158
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2025",
    "title": "Årsredovisning 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a0917f6991d6c3be300cd92421349d4be",
    "date": "2026-04-17",
    "period": "2025-annual",
    "form_type": "annual-report",
    "report_key": "2025:annual",
    "filename": "04169804.pdf",
    "text_chars": 236130,
    "sha256": "40d505db6959517a590cdf9507121369e549bd7c7964ac2a2613ac4f99c0d832",
    "url": "/company/moberg-pharma/documents/nasdaq-nordic-arsredovisning-2025",
    "absolute_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-arsredovisning-2025",
    "txt_url": "/company/moberg-pharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/moberg-pharma/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
        "chars": 177675
      },
      {
        "number": 2,
        "url": "/company/moberg-pharma/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
        "chars": 58453
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
    "title": "Kvartalsrapport Q4 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/acc11051b4d2bceb57dbf5b2a9ba1ff69",
    "date": "2026-02-17",
    "period": "2025-q4",
    "form_type": "year-end-report",
    "report_key": "2025:q4",
    "filename": "02161823.pdf",
    "text_chars": 42700,
    "sha256": "5669c83cdc53f4b22974c53dbab55ceb39718ea34c3a741e04baba6cbc97af06",
    "url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
    "absolute_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
    "txt_url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
        "chars": 42700
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
    "title": "Kvartalsrapport Q3 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a178f416752247c2e0c187254b6798490",
    "date": "2025-11-11",
    "period": "2025-q3",
    "form_type": "interim-report",
    "report_key": "2025:q3",
    "filename": "11107927.pdf",
    "text_chars": 46645,
    "sha256": "7e4e9819200e47890c19f17e84f6d0d6b47e7a5f6eccada7010068b139befc67",
    "url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
    "absolute_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
    "txt_url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
        "chars": 46645
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
    "title": "Kvartalsrapport Q2 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ac241e37e905facaca03e613f2fe29308",
    "date": "2025-08-12",
    "period": "2025-q2",
    "form_type": "interim-report",
    "report_key": "2025:q2",
    "filename": "08119244.pdf",
    "text_chars": 42376,
    "sha256": "73b37b43414bf55370ccc87264a3b665f50ee25abe61b05a9700794d7fffcce8",
    "url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
    "absolute_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
    "txt_url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
        "chars": 42376
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
    "title": "Kvartalsrapport Q1 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a53a15141ad43e9c9a9b3d1313756c139",
    "date": "2025-05-13",
    "period": "2025-q1",
    "form_type": "interim-report",
    "report_key": "2025:q1",
    "filename": "05120994.pdf",
    "text_chars": 40066,
    "sha256": "5f81368e9e8cb83ef48f8c90fb48c0b3bb319547a31c40892f0a3554a031f960",
    "url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
    "absolute_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
    "txt_url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
        "chars": 40066
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2024",
    "title": "Årsredovisning 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a49c5138d6bfe58b2666822812b59f4cc",
    "date": "2025-04-11",
    "period": "2024-annual",
    "form_type": "annual-report",
    "report_key": "2024:annual",
    "filename": "04105917.pdf",
    "text_chars": 237739,
    "sha256": "952c67c09b3a817cc9600b274370a0720b40aed9751b45fc8f8343d41f6b3342",
    "url": "/company/moberg-pharma/documents/nasdaq-nordic-arsredovisning-2024",
    "absolute_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-arsredovisning-2024",
    "txt_url": "/company/moberg-pharma/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/moberg-pharma/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
        "chars": 179289
      },
      {
        "number": 2,
        "url": "/company/moberg-pharma/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
        "chars": 58448
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
    "title": "Kvartalsrapport Q4 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a49d7fcb0776498422b629a0d11658605",
    "date": "2025-02-11",
    "period": "2024-q4",
    "form_type": "year-end-report",
    "report_key": "2024:q4",
    "filename": "02104805.pdf",
    "text_chars": 45172,
    "sha256": "23d6c80cd1b24799649963b2004f5e86f8e0fc2580591994c7a4dffaa2b55c4e",
    "url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
    "absolute_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
    "txt_url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
        "chars": 45172
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
    "title": "Kvartalsrapport Q3 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a80f1a2120999595c11908852743cde4c",
    "date": "2024-11-12",
    "period": "2024-q3",
    "form_type": "interim-report",
    "report_key": "2024:q3",
    "filename": "11115568.pdf",
    "text_chars": 46994,
    "sha256": "605be590ea4094ba24a78272e651a3962e214d36b253761bc65ef6417ce9aaa9",
    "url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
    "absolute_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
    "txt_url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
        "chars": 46994
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
    "title": "Kvartalsrapport Q2 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ad8c9de2d124edc7dc67a43c48400493d",
    "date": "2024-08-13",
    "period": "2024-q2",
    "form_type": "interim-report",
    "report_key": "2024:q2",
    "filename": "08124063.pdf",
    "text_chars": 42791,
    "sha256": "4434f8270a18cbbdc489caf4ade80d572d66aceaf88d6372284070856e0f8647",
    "url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
    "absolute_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
    "txt_url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
        "chars": 42791
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
    "title": "Kvartalsrapport Q1 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ac4858f04198212185bf639dd1ab14e12",
    "date": "2024-05-07",
    "period": "2024-q1",
    "form_type": "interim-report",
    "report_key": "2024:q1",
    "filename": "05064576.pdf",
    "text_chars": 39027,
    "sha256": "191531dfa0611531ab7b62a7617f4498806249ce5b012d7f92d420b336202034",
    "url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
    "absolute_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
    "txt_url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
        "chars": 39027
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2023",
    "title": "Årsredovisning 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/aa992845d56c11ed656a9e84a2417670a",
    "date": "2024-04-12",
    "period": "2023-annual",
    "form_type": "annual-report",
    "report_key": "2023:annual",
    "filename": "04110439.pdf",
    "text_chars": 236217,
    "sha256": "35d5862def1400adb3c8886f003cc0bdadb010b6eb94798b112c55125e05e461",
    "url": "/company/moberg-pharma/documents/nasdaq-nordic-arsredovisning-2023",
    "absolute_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-arsredovisning-2023",
    "txt_url": "/company/moberg-pharma/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/moberg-pharma/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
        "chars": 178691
      },
      {
        "number": 2,
        "url": "/company/moberg-pharma/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
        "chars": 57524
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
    "title": "Kvartalsrapport Q4 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a18b0f28e1473af0169520a46183acb6d",
    "date": "2024-02-13",
    "period": "2023-q4",
    "form_type": "year-end-report",
    "report_key": "2023:q4",
    "filename": "02126814.pdf",
    "text_chars": 41832,
    "sha256": "2ea9b564a8142e5b48190c78bd69c156624a7f2a277a8562b2733aa12446a2e4",
    "url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
    "absolute_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
    "txt_url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
        "chars": 41832
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
    "title": "Kvartalsrapport Q3 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a13541e6792fa90aacea1c7c49dcc5d72",
    "date": "2023-11-07",
    "period": "2023-q3",
    "form_type": "interim-report",
    "report_key": "2023:q3",
    "filename": "11069198.pdf",
    "text_chars": 44269,
    "sha256": "f5e96900782a0e062251b8a70fa43050da7f0e4490216e0158a22d679d1f8077",
    "url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
    "absolute_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
    "txt_url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
        "chars": 44269
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
    "title": "Kvartalsrapport Q2 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a3ace2efddca7c5f5f301e7a02b74dff4",
    "date": "2023-08-03",
    "period": "2023-q2",
    "form_type": "interim-report",
    "report_key": "2023:q2",
    "filename": "08021298.pdf",
    "text_chars": 40267,
    "sha256": "4b01c41ebadd918f34d97d01cf82049932396e2eadaa2fc1a503995ff3c2f3d0",
    "url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
    "absolute_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
    "txt_url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
        "chars": 40267
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
    "title": "Kvartalsrapport Q1 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a48aae1f357bb375199230e6b5ed706ad",
    "date": "2023-05-09",
    "period": "2023-q1",
    "form_type": "interim-report",
    "report_key": "2023:q1",
    "filename": "05084027.pdf",
    "text_chars": 32537,
    "sha256": "46e2f3a7c3f65a498963bae953eda6477c4a41b7a28e0175c548cbe4dc5acc7a",
    "url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
    "absolute_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
    "txt_url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/moberg-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
        "chars": 32537
      }
    ]
  },
  {
    "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata",
    "title": "MFN bolagssida och bolagsmetadata",
    "source": "MFN",
    "source_class": "mfn",
    "source_url": "https://mfn.se/all/a/moberg-pharma",
    "date": null,
    "period": null,
    "form_type": "company-page",
    "report_key": null,
    "filename": "company.txt",
    "text_chars": 13287,
    "sha256": "85625de7b40075ccacaa1ad9f090d31ca0fd6c545868096c9a9aa8b9fb306426",
    "url": "/company/moberg-pharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
    "absolute_url": "https://spela.port0.org/company/moberg-pharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
    "txt_url": "/company/moberg-pharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/moberg-pharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/moberg-pharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html",
        "chars": 13287
      }
    ]
  }
]